Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israel, Tel Aviv
Michael Shapira
36 years of experience
Clinic is certified :
The total cost of myeloma treatment in Israel is determined by the specific treatment plan. Initial diagnostics are priced at $800, while cart treatment for myeloma ranges from $80,000 to $120,000.The treatment program is tailored following the doctor"s individual assessment of each patient.
| Israel | Turkey | Austria | |
| Plasmapheresis | from $2,200 | from $1,200 | from $2,000 |
| Therapeutic Apheresis | - | from $1,350 | - |
| Plasma Exchange | - | from $3,900 | - |
| DFPP Plasmapheresis | - | from $1,850 | - |
Professor Ron Ram practices at Sourasky Medical Center (Ichilov), Israel's largest university hospital.
Dr. Ron Ram has performed several hundred stem cell transplants at Sourasky Medical Center – a key procedure for treating Myeloma.
Dr. El Hasid has conducted over 300 bone marrow and cord blood transplants for children. She leads the Pediatric Oncohematology and Oncology Department at Dana Dwek Children's Hospital.
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.